Analysis of CDK12 alterations in a pan-cancer database.

ABSTRACT:

Background

CDK12 inactivation leading to increased neoantigen burden has been hypothesized to sensitize tumors to immune checkpoint inhibition. Pan-cancer data regarding the frequency of CDK12 alterations are limited. We aimed to characterize CDK12 alterations across all cancer types through real-world clinical-grade sequencing.

Methods

This was a single-center retrospective analysis of 4994 cancer patients who underwent tissue or blood genomic profiling, including CDK12 assessment, conducted as part of routine care from December 2012 to January 2020. Prevalence, clinical characteristics, and treatment outcomes of patients with tumors with pathogenic CDK12 alterations were described.

Results

In all, 39 (0.78%, n = 39/4994) patients had pathogenic CDK12 alterations. Am

SUBMITTER: Pan E 

PROVIDER: S-EPMC8817093 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature